English
Regional settings| Spread | 0.04 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 4.06 |
| Open | 4 |
| 1-Year Change | -41.09% |
| Day's Range | 3.99 - 4.06 |
Akoya Biosciences, Inc. is a life sciences technology company. The Company deliveries spatial biology solutions, which is focused on transforming discovery and clinical research. Spatial biology technology enables academic and biopharma scientists to detect and map the distribution of cell types and biomarkers across whole tissue samples at single-cell resolution, enabling advancements in their understanding of disease progression and patient response to therapy. Through its PhenoCycler and and PhenoImager platform, reagents, software and services, it offers end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research. It provides PhenoImager HT, which is a digital pathology slide scanner featuring MOTiF whole-slide multispectral scanning of up to seven biomarkers with an 80-slide capacity. It offers contract research services laboratory, which is called as advanced biopharma solutions.
BRIEF: For the fiscal year ended 31 December 2021, Akoya Biosciences Inc revenues increased 29% to $54.9M. Net loss applicable to common stockholders increased from $21.8M to $44.4M. Revenues reflect Consumables segment increase of 68% to $14.3M, Instruments segment increase of 21% to $28.7M, North America segment increase of 39% to $28M, EMEA segment increase of 21% to $14.4M. Higher net loss reflects Selling.
